INTRODUCTION
Neoadjuvant radiation therapy (NRT) is beneficial in gastrointestinal cancers, but its role in pancreatic ductal adenocarcinoma (PDAC) remains uncertain. It is unclear if hospital-level NRT volume is an important factor when treating PDAC with NRT.
METHODS
The National Cancer Database (2011-2019) was use...
A. Pannekoek, R. Narayan, Amanda Carlson et al.· Journal of Surgical Oncology· 0 citations
Pancreatic re-RT is feasible and may offer promising local control and time off chemotherapy for selected patients, and improvements in RT delivery with online adaptive therapy may further minimize toxicity.
Helen X. Hou, Hannah J. Roberts, P. Pathak et al.· American Journal of Clinical...· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cell· 0 citations
IL-21-elicited CD4 T cells exert anti-tumor activity in mice, and potentially in humans, which can convert transient responses to KRAS inhibition into durable remissions in pancreatic cancer.
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.